Therefore, for the meta-analysis, five [14,15,17,18,19] and four [16,17,19,20] articles were considered to assess changes in gal-3 and MPO levels, respectively, before and after the cancer treatment (Tables S1 and S2). The gene discussed is LGALS3; the disease is cancer.